• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

慢性淋巴细胞白血病的治疗靶点

Therapeutic Targets in Chronic Lymphocytic Leukemia.

作者信息

Laurenti Luca, Efremov Dimitar G

机构信息

Department of Hematology, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy.

Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, 34149 Trieste, Italy.

出版信息

Cancers (Basel). 2020 Nov 4;12(11):3259. doi: 10.3390/cancers12113259.

DOI:10.3390/cancers12113259
PMID:33158264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7694246/
Abstract

Chronic lymphocytic leukemia (CLL) is a common B cell malignancy and is the most common type of adult leukemia in western countries [...].

摘要

慢性淋巴细胞白血病（CLL）是一种常见的B细胞恶性肿瘤，是西方国家最常见的成人白血病类型[……]

相似文献

1
Therapeutic Targets in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病的治疗靶点
Cancers (Basel). 2020 Nov 4;12(11):3259. doi: 10.3390/cancers12113259.
2
Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan.慢性淋巴细胞白血病（CLL）较为罕见，但在日本，T细胞型慢性淋巴细胞白血病（T-CLL）的比例较高。
Eur J Haematol. 2001 Sep;67(3):152-7. doi: 10.1034/j.1600-0609.2001.5790514.x.
3
Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death.患有慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的退伍军人发生第二种恶性肿瘤的几率显著增加，这是最常见的死亡原因。
Leuk Lymphoma. 2004 Mar;45(3):507-13. doi: 10.1080/10428190310001612939.
4
[A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].[1例慢性淋巴细胞白血病治疗期间发生慢性髓系白血病的病例]
Gan To Kagaku Ryoho. 2011 Feb;38(2):333-6.
5
Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease?小淋巴细胞淋巴瘤和慢性淋巴细胞白血病：它们是同一种疾病吗？
Cancer J. 2012 Sep-Oct;18(5):396-403. doi: 10.1097/PPO.0b013e31826cda2d.
6
Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia.常见B细胞慢性淋巴细胞白血病中使用的VH5基因缺乏广泛突变。
J Exp Med. 1993 Apr 1;177(4):1039-46. doi: 10.1084/jem.177.4.1039.
7
Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.肝细胞生长因子诱导慢性淋巴细胞白血病的生存及免疫抑制作用
Curr Mol Med. 2017;17(1):24-33. doi: 10.2174/1566524017666170220095838.
8
Functional proteomic insights in B-cell chronic lymphocytic leukemia.B细胞慢性淋巴细胞白血病的功能蛋白质组学见解
Expert Rev Proteomics. 2017 Feb;14(2):137-146. doi: 10.1080/14789450.2017.1275967. Epub 2016 Dec 30.
9
Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL).NAD 依赖性脱乙酰酶 SIRT1 和 SIRT2 在 B 细胞慢性淋巴细胞白血病（CLL）中的功能特性
Cancer Biol Ther. 2016;17(3):300-9. doi: 10.1080/15384047.2016.1139246. Epub 2016 Jan 21.
10
Animal models for chronic lymphocytic leukemia.慢性淋巴细胞白血病的动物模型
J Cell Biochem. 2007 Apr 1;100(5):1109-18. doi: 10.1002/jcb.21147.

引用本文的文献

1
B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.慢性淋巴细胞白血病发病机制中的B细胞受体信号传导及相关通路
Front Oncol. 2024 Feb 26;14:1339620. doi: 10.3389/fonc.2024.1339620. eCollection 2024.
2
Immunoglobulin Gene Sequence as an Inherited and Acquired Risk Factor for Chronic Lymphocytic Leukemia.免疫球蛋白基因序列作为慢性淋巴细胞白血病的遗传和获得性风险因素
Cancers (Basel). 2022 Jun 21;14(13):3045. doi: 10.3390/cancers14133045.

本文引用的文献

1
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.奥滨尤妥珠单抗、伊布替尼和维奈克拉联合治疗初治和复发/难治性慢性淋巴细胞白血病的 II 期研究。
J Clin Oncol. 2020 Nov 1;38(31):3626-3637. doi: 10.1200/JCO.20.00491. Epub 2020 Aug 14.
2
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.伊布替尼或 venetoclax 治疗后 Bcl-2 家族成员的变化揭示了决定 CLL 对 venetoclax 耐药性的功能层次。
Blood. 2020 Dec 17;136(25):2918-2926. doi: 10.1182/blood.2019004326.
3
Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.B细胞受体激活机制及B细胞恶性肿瘤对B细胞受体抑制剂的反应
Cancers (Basel). 2020 May 28;12(6):1396. doi: 10.3390/cancers12061396.
4
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.华氏巨球蛋白血症中伊布替尼耐药克隆的基因组进化。
Br J Haematol. 2020 Jun;189(6):1165-1170. doi: 10.1111/bjh.16463. Epub 2020 Feb 27.
5
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.在 Venetoclax 治疗慢性淋巴细胞白血病的进展中，出现了 BCL2 多个突变与 Gly101Val 共存的情况。
Blood. 2020 Mar 5;135(10):773-777. doi: 10.1182/blood.2019004205.
6
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.线粒体重编程是淋巴恶性肿瘤对 BCL-2 抑制产生耐药的基础。
Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.
7
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.伊布替尼联合维奈托克治疗复发/难治性慢性淋巴细胞白血病：CLARITY 研究。
J Clin Oncol. 2019 Oct 20;37(30):2722-2729. doi: 10.1200/JCO.19.00894. Epub 2019 Jul 11.
8
Chronic lymphocytic leukaemia: from genetics to treatment.慢性淋巴细胞白血病：从遗传学治疗。
Nat Rev Clin Oncol. 2019 Nov;16(11):684-701. doi: 10.1038/s41571-019-0239-8.
9
Ibrutinib and Venetoclax for First-Line Treatment of CLL.伊布替尼联合维奈托克用于初治 CLL 患者。
N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.
10
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Venetoclax 治疗复发慢性淋巴细胞白血病的疗效受疾病和应答变量的影响。
Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.